Artelo Biosciences terminates ATM offering agreement with R.F. Lafferty; minimal prior sales

ARTELO BIOSCIENCES, INC.

Termination notice issued May 11, 2026; effective May 18, 2026.
Agreement allowed up to $6.5M in common stock sales; only 50,858 shares sold for $451,527 gross proceeds.
ATM program was entered July 18, 2025 and never significantly utilized.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ARTELO BIOSCIENCES, INC. terminated Sales Agreement with R.F. Lafferty & Co., Inc. valued at up to $6,500,000 (effective 2026-05-18).

Action: termination
Agreement: atm program
Counterparty: R.F. Lafferty & Co., Inc.
Value: up to $6,500,000
Effective: 2026-05-18

Exact text from the filing

On May 11, 2026, Artelo Biosciences, Inc. (the “Company”) provided notice to R.F. Lafferty & Co., Inc. (“R.F. Lafferty”) of its election to terminate that certain At-The-Market Offering Agreement, dated July 18, 2025, by and between the Company and R.F. Lafferty (the “Sales Agreement”), which termination will be effective on May 18, 2026, in accordance with the terms of the Sales Agreement.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

ARTELO BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001640334-26-000903

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.